Quick Answer
HUTCHMED (China) Ltd reported R&D Expense of $148.29 million for fiscal year 2025.
HUTCHMED (China) Ltd R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $148.29M | -30.1% |
| 2024 | $212.11M | -29.8% |
| 2023 | $302.00M | -21.9% |
| 2022 | $386.89M | +29.4% |
| 2021 | $299.09M | +71.1% |
| 2020 | $174.78M | +26.5% |
| 2019 | $138.19M | +21.0% |
| 2018 | $114.16M | +51.2% |
| 2017 | $75.52M | +12.9% |
| 2016 | $66.87M | +41.2% |
| 2015 | $47.37M | +58.3% |
| 2014 | $29.91M | — |
- HUTCHMED (China) Ltd showed a decrease of -30.1% in R&D Expense compared to the prior fiscal year.
- Over the 2014–2025 period, HUTCHMED (China) Ltd’s r&d expense has grown by 395.7% (from $29.91 million to $148.29 million).
- The most recent figure is from HUTCHMED (China) Ltd’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: